Seattle, July 16, 2018 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global metabolism drugs market was valued at US$ 5,765.3 million in 2017 and is projected to exhibit a CAGR of 6.3% over the forecast period (2018–2026).
To know the latest trends and insights prevalent in this market, click the link below:
https://www.coherentmarketinsights.com/market-insight/metabolism-drugs-market-1955
Key Trends and Analysis of the Metabolism Drugs Market:
Manufacturers are actively working on developing new therapies for various metabolic diseases. For instance, various pipeline products include NeoGAA GZ402666 (Sanofi) in phase 3, AT-982 in phase 3 (Audentes Therapeutics)), and BMN 701 in phase 2 (BioMarin Pharmaceutical, Inc.) clinical trial are also expected to create a meteoric growth in this market during the forecast period.
Amicus Therapeutics was granted with orphan drug designation for its investigational combination drug therapy ATB200/AT2221 in November 2017. This drug is intended to cure Pompe disease (acid maltase deficiency or AMD). in March 2018, Shire plc entered into a preclinical research collaboration with NanoMedSyn— French biotech company—to develop enzyme replacement treatment for a lysosomal storage disorder based on NanoMedSyn’s synthetic derivative technology named AMFA.
Lixte Biotechnology Holdings, Inc., has LB-201/LB-205 in the preclinical stage, JCR Pharmaceuticals Co. Ltd. filed for JR-051 in Japan in 2017, and has many other products in the pipeline for metabolic diseases. Moreover, manufacturers such as Pharming Group NV, and Orphazyme ApS have products in the pipeline for metabolic diseases.
Moreover, in 2017, Research funded by the National Institute of Neurological Disorders and Stroke (NINDS) has shown that viral-delivered gene therapy can stop the buildup materials stored in the brain cells and improve memory and learning. High return on investments, health insurance coverage, and various reimbursement policies for such costly drugs are influencing pharmaceutical companies to invest in drug development.
Request Sample Pages of the Report
Key Market Takeaways:
- The market is expected to exhibit CAGR of 6.3% during the forecast period (2018–2026). This growth is attributed to increasing adoption of various available therapies such as enzyme replacement therapy, and wide availability of products
- Several enzyme replacement therapies, and gene therapies are under development stage, which is expected to aid in market growth in the near future
- North America and Europe are expected to witness significant growth due to presence of leading manufacturers such as Shire Plc, and Genzyme Corporation
- Some of the players operating in the global metabolism drugs market are Merck & Co., Inc., Novartis AG, Amicus Therapeutics, AstraZeneca Plc, Boehringer Ingelheim, Shire Plc, Sanofi Genzyme, BioMarin Pharmaceutical, Inc., Horizon Pharma Plc, and GlaxoSmithKline Plc.